Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 396-402

  Dai, Chia Yen ^a,b   Chuang, Wan Long ^a,c   Hsieh, Ming Yen ^a   Huang, Jee Fu ^a,c   Lin, Ya Yun ^a   Chu, Pei Yu ^d   Hou, Nai Jen ^a,c   Lin, Zu Yau ^a,b   Chen, Shinn Cherng ^a,b   Hsieh, Ming Yuh ^a,b   Wang, Liang Yen ^a,b   Yu, Ming Lung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatitis C virus; Human leukocyte antigen; Pegylated interferon; Ribavirin; Sustained virological response

Indexed keywords

HLA A24 ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B40 ANTIGEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALLELE; ANTIGEN EXPRESSION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TAIWAN; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENE FREQUENCY; HAPLOTYPES; HEPATITIS C, CHRONIC; HLA ANTIGENS; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 74449083238     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.11.006     Document Type: Article

References (44)

1. Alberti A., and Benvegnù L. Management of hepatitis C. J. Hepatol. 1 38 (2003) S104-S118
2. Almarri A., El Dwick N., Al Kabi S., Sleem K., Rashed A., Ritter M.A., and Batchelor J.R. Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum. Immunol. 59 (1998) 239-242
3. Alric L., Fort M., Izopet J., Vinel J.P., Charlet J.P., Selves J., Puel J., Pascal J.P., Duffaut M., and Abbal M. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 113 (1997) 1675-1681
4. Alric L., Izopet J., Fort M., Vinel J.P., Fontenelle P., Orfila C., Payen J.L., Sandres K., Desmorat H., Charlet J.P., Duffaut M., and Abbal M. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum. Immunol. 60 (1999) 516-523
5. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
6. Chuang W.L., Yu M.L., Dai C.Y., and Chang W.Y. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 49 (2006) 99-106
7. Dai C.Y., Chuang W.L., Chang W.Y., Chen S.C., Lee L.P., Hsieh M.Y., Hou N.J., Lin Z.Y., Hsieh M.Y., Wang L.Y., and Yu M.L. Polymorphisms in the interferon-γ gene at position +874 in patients with chronic hepatitis C treated with high dose interferon-α and ribavirin. Antiviral Res. 67 (2005) 93-97
8. Dai C.Y., Chuang W.L., Chang W.Y., Chen S.C., Lee L.P., Hsieh M.Y., Hou N.J., Lin Z.Y., Huang J.F., Hsieh M.Y., Wang L.Y., and Yu M.L. Tumor necrosis factor alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J. Infect. Dis. 193 (2006) 98-101
9. Dai C.Y., Chuang W.L., Ho C.K., Hsieh M.Y., Huang J.F., Lee L.P., Hou N.J., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Tsai J.F., Chang W.Y., and Yu M.L. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J. Hepatol. 49 (2008) 9-16
10. Dai C.Y., Huang J.F., Hsieh M.Y., Hou N.J., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Chuang W.L., and Yu M.L. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol. 50 (2009) 712-718
11. Fanning L.J., Levis J., Kenny-Walsh E., Whelton M., O'Sullivan K., and Shanahan F. HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology 33 (2001) 224-230
12. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer Jr. H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., Ackrill A.M., and PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140 (2004) 346-355
13. Höhler T., Gerken G., Notghi A., Knolle P., Lubjuhn R., Taheri H., Schneider P.M., Meyer zum Büschenfelde K.H., and Rittner C. MHC class II genes influence the susceptibility to chronic active hepatitis C. J. Hepatol. 27 (1997) 259-264
14. Jiao J., and Wang J.B. Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C. Hepatobiliary Pancreat. Dis. Int. 4 (2005) 80-83
15. Kaslow R.A., Carrington M., Apple R., Park L., Muñoz A., Saah A.J., Goedert J.J., Winkler C., O'Brien S.J., Rinaldo C., Detels R., Blattner W., Phair J., Erlich H., and Mann D.L. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2 (1996) 405-411
16. Kikuchi I., Ueda A., Mihara K., Miyanaga O., Machidori H., Ishikawa E., and Tamura K. The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 10 (1998) 859-863
17. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., Kiernan T.W., and Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
18. Koziel M.J. The role of immune responses in the pathogenesis of hepatitis C virus infection. J. Viral Hepat. 4 2 (1997) 31-41
19. Kurokohchi K., Arima K., and Nishioka M. A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. J. Hepatol. 34 (2001) 930-935
20. Lau J.Y., Tam R.C., Liang T.J., and Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 (2002) 1002-1009
21. Lechmann M., Schneider E.M., Giers G., Kaiser R., Dumoulin F.L., Sauerbruch T., and Spengler U. Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur. J. Clin. Invest. 29 (1999) 337-343
22. Morishima C., Polyak S.J., Ray R., Doherty M.C., Di Bisceglie A.M., Malet P.F., Bonkovsky H.L., Sullivan D.G., Gretch D.R., Rothman A.L., Koziel M.J., Lindsay K.L., and Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J. Infect. Dis. 193 (2006) 931-940
23. NIH Consensus Statement on Management of Hepatitis C. NIH Consens State Sci Statements 19 (2002) 1-46
24. Okamoto H., Tokita H., Sakamoto M., Horikita M., Kojima M., Iizuka H., and Mishiro S. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J. Gen. Virol. 74 (1993) 2385-2390
25. Perneger T.V. What's wrong with Bonferroni adjustments. BMJ 316 (1998) 1236-1238
26. Roger M. Influence of host genes on HIV-1 disease progression. FASEB J. 12 (1998) 625-632
27. Romero-Gómez M., González-Escribano M.F., Torres B., Barroso N., Montes-Cano M.A., Sánchez-Muñoz D., Núñez-Roldan A., and Aguilar-Reina J. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Am. J. Gastroenterol. 98 (2003) 1621-1626
28. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 13 (1991) 372-374
29. Schipper R.F., D'Amaro J., Bakker J.T., Bakker J., van Rood J.J., and Oudshoorn M. HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum. Immunol. 52 (1997) 54-71
30. Shaw C.K., Chen L.L., Lee A., and Lee T.D. Distribution of HLA gene and haplotype frequencies in Taiwan: a comparative study among Min-nan, Hakka, Aborigines and Mainland Chinese. Tissue Antigens 53 (1999) 51-64
31. Sim H., Wojcik J., Margulies M., Wade J.A., and Heathcote J. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J. Viral Hepat. 5 (1998) 249-253
32. Strader D.B., Wright T., Thomas D.L., Seeff L.B., and American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
33. Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., and Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 30 (1999) 376-382
34. Thio C.L., Gao X., Goedert J.J., Vlahov D., Nelson K.E., Hilgartner M.W., O'Brien S.J., Karacki P., Astemborski J., Carrington M., and Thomas D.L. HLA-Cw*04 and hepatitis C virus persistence. J. Virol. 76 (2002) 4792-4797
35. Thomas H.C., and Thursz M.R. Immunogenetics of hepatitis B virus infection. J. Viral Hepat. 4 2 (1997) 98-100
36. Thursz M., Yallop R., Goldin R., Trépo C., and Thomas H.C. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354 (1999) 2119-2124
37. Tokunaga K., Ohashi J., Bannai M., and Juji T. Genetic link between Asians and native Americans: evidence from HLA genes and haplotypes. Hum. Immunol. 62 (2001) 1001-1008
38. Yu M.L., Dai C.Y., Chen S.C., Chiu C.C., Lee L.P., Lin Z.Y., Hsieh M.Y., Wang L.Y., Chuang W.L., and Chang W.Y. Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment in Taiwanese patients with chronic hepatitis C virus infection. J. Infect. Dis. 188 (2003) 62-65
39. Yu M.L., Dai C.Y., Chen S.C., Lee L.P., Huang J.F., Lin Z.Y., Hsieh M.Y., Wang L.Y., Chuang W.L., and Chang W.Y. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res. 63 (2004) 25-32
40. Yu M.L., Chuang W.L., Dai C.Y., Lee L.P., Hsieh M.Y., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., Tsai S.L., and Kuo H.T. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl. Res. 148 (2006) 120-127
41. Yu M.L., Dai C.Y., Huang J.F., Hou N.J., Lee L.P., Hsieh M.Y., Chiu C.F., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., and Chuang W.L. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56 (2007) 553-559
42. Yu M.L., Dai C.Y., Huang J.F., Chiu C.F., Yang Y.H., Hou N.J., Lee L.P., Hsieh M.Y., Lin Z.Y., Chen S.C., Hsieh M.Y., Wang L.Y., Chang W.Y., and Chuang W.L. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 47 (2008) 1884-1893
43. Wawrzynowicz-Syczewska M., Underhill J.A., Clare M.A., Boron-Kaczmarska A., McFarlane I.G., and Donaldson P.T. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland. Liver 20 (2000) 234-239
44. Zavaglia C., Bortolon C., Ferrioli G., Rho A., Mondazzi L., Bottelli R., Ghessi A., Gelosa F., Iamoni G., and Ideo G. HLA typing in chronic type B, D and C hepatitis. J. Hepatol. 24 (1996) 658-665